By HealthDataConsortium.org Research Team
Specimen validity testing is a separate check built into standard urine drug testing to confirm that a sample is consistent with normal human urine before any drug result is relied on. A detox product or a large volume of fluid can change how diluted a urine sample is, but it has no influence on which validity markers a laboratory checks, what thresholds apply to those markers, or how a reviewing physician handles an abnormal result. Understanding why validity testing exists, and why it runs on a different track than the drug screen itself, explains why dilution carries a documented risk that has nothing to do with whether a drug or its metabolites are actually present.
What Specimen Validity Testing Measures
Specimen validity testing (SVT) is a defined step in federal workplace drug testing, separate from the drug screen itself. Its purpose is to determine whether a urine specimen is consistent with normal human physiology. Laboratories assess this using a small set of chemical markers:
- Creatinine concentration — a normal waste product in urine; an abnormally low level is a key indicator used to flag a specimen as dilute or substituted
- Specific gravity — a measure of how concentrated a sample is, evaluated alongside creatinine
- pH — normal human urine falls within an expected range; a pH well outside that range can point to an added substance
- Oxidants and other adulterants — laboratories test specifically for substances introduced to interfere with detecting a drug or its metabolites
These markers are what separate the categories a lab can report: a dilute specimen (creatinine and specific gravity lower than expected), an adulterated specimen (a substance present that doesn’t belong in normal urine, or a normal substance at an abnormal level), or a substituted specimen (values so far outside the physiological range that the lab determines the sample likely isn’t human urine). None of these categories measures a specific drug — each measures whether the specimen itself looks like it came from a person under normal conditions.
Why This Is a Separate Process From Screening and Confirmation
It’s easy to assume a drug test produces one combined outcome, but validity testing, initial screening, and confirmatory testing are distinct steps that can report different results. A specimen can screen negative for a drug and still be flagged as dilute, adulterated, or substituted based entirely on its chemical validity markers — a finding reported and reviewed on its own. Readers researching how long THC metabolites can remain detectable in urine are often thinking about a different variable than the one validity testing checks: detection windows relate to the drug screen, while validity status relates to whether the specimen is credible as a normal biological sample.
How an Abnormal Validity Result Is Handled
Under the DOT testing rule (49 CFR Part 40), a Medical Review Officer (MRO) — a licensed physician trained in this specific review process — is responsible for evaluating any confirmed positive, dilute, adulterated, substituted, or invalid result before it reaches an employer. A few features of that review are worth understanding:
- For a negative specimen also reported as dilute, if the creatinine concentration falls between 2 and 5 mg/dL, the MRO is required to direct an immediate recollection under direct observation.
- An adulterated or substituted finding is handled by the MRO the same way a confirmed positive drug result is handled, including a verification interview with the person tested.
- The regulation specifically limits what the MRO can accept as an explanation. An MRO cannot accept an assertion that common adulterants such as soap, bleach, or glutaraldehyde entered a specimen through physiological means, because no physiological pathway produces that result. An MRO likewise cannot accept a claim that a person naturally produced urine with creatinine below the laboratory’s detection limit, since there is no physiological explanation that fits that outcome either.
This review structure exists because validity markers can be affected by actions taken before a test is given — which is exactly why a trained reviewer, not a product label, determines how an abnormal result is resolved.
Where Detox and Dilution Marketing Misses the Point
Products marketed as detox drinks or cleanses generally work, to the extent they work at all, by encouraging enough fluid intake to temporarily lower the concentration of a urine sample. But concentration is exactly what creatinine and specific gravity measurements are built to detect. A specimen diluted enough to lower a drug concentration is, by the same chemistry, more likely to land in the range that validity testing flags as dilute or substituted. No marketing claim changes which validity markers a lab tests for or what thresholds apply — those are fixed by the testing framework, not by anything a consumer product can influence. That’s the core limitation behind detox-drink and “flush” marketing generally: these products target fluid concentration, which is one of several independent variables a specimen is evaluated on — not a variable a consumer can selectively control.
The same gap shows up across detox product marketing more broadly. A useful test for any such claim is to ask what variable it says it controls, and whether that’s actually the variable a validity check measures. A consumer checklist for evaluating detox marketing claims walks through that distinction in more detail, and the same principle — that a marketed product cannot control a regulated laboratory process — applies whether the concern is the drug screen, the validity check, or a separate issue like CBD use and false-positive risk.
The Takeaway
Specimen validity testing is an independent part of standard urine drug testing, built around measurable chemistry — creatinine, specific gravity, pH, and adulterant screening — not around guesswork about what a person did before providing a sample. It runs alongside, not instead of, the drug screen and confirmation testing, and an abnormal result goes through a separate, physician-led review with specific rules about what explanations can and cannot be accepted. Dilution in particular is a variable that validity testing is specifically designed to catch, regardless of what a product label claims.
Sources:
- 49 CFR §40.155 — What does the MRO do when a negative or positive test result is also dilute?
- 49 CFR §40.151 — What are MROs prohibited from doing as part of the verification process?
- 49 CFR §40.145 — On what basis does the MRO verify test results involving adulteration or substitution?
